Sublingual Immunotherapy

Publication Date: May 1, 2017

Key Points

Key Points

  • It is crucial that the practicing allergist separate the data on FDA reviewed products that have led to approval of these products (ie, dust mites, grass and ragweed tablets) from the data in the literature with other allergens and other formulations (eg, liquid formulations) that have not undergone the rigor of FDA review.

Diagnosis

...iagnosis...

...e 1. World Allergy Organization Grading System...


.... Description of Local Adverse Effects Related t...


Treatment

...atment...

...FDA-approved SLIT products for the treatment...


...he physician should be aware that SLIT may...


...-approved SLIT products very cauti...


...dosing equivalence between SLIT tablets an...


...minister the patient’s first dose of SLIT in a...


...ribe epinephrine (either an autoinject...


Reduce a patient’s SLIT dose if they have m...


...edule patients receiving SLIT therapy for r...


...ts for SLIT in the United States are the 5-gras...


.... Suggested Guidelines for the Practicin...


.... FDA-Approved Sublingual TabletsHaving trouble...